GeoVax Labs is a clinical-stage biotechnology company based in Atlanta, GA, specializing in the development of innovative therapies and vaccines for cancer and infectious diseases. Their current focus includes a Phase 1/2 clinical trial for Gedeptin, a promising treatment for advanced head and neck cancers, and two Phase 2 trials for CM04S1, a next-generation Covid-19 vaccine designed for high-risk immunocompromised patients.
With a dedicated team of experts and collaborations with renowned scientific advisors, GeoVax is at the forefront of immunology innovations, aiming to address some of the world's most challenging health threats. Through their cutting-edge MVA-VLP and Gedeptin technologies, GeoVax is committed to making significant contributions to the field of biotechnology and improving global health outcomes.
Generated from the website